You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 10, 2024

RYKINDO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Rykindo, and what generic alternatives are available?

Rykindo is a drug marketed by Shandong Luye and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-six patent family members in fourteen countries.

The generic ingredient in RYKINDO is risperidone. There are thirty drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the risperidone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rykindo

A generic version of RYKINDO was approved as risperidone by APOTEX INC on September 15th, 2008.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RYKINDO?
  • What are the global sales for RYKINDO?
  • What is Average Wholesale Price for RYKINDO?
Summary for RYKINDO
International Patents:36
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 143
Patent Applications: 4,071
What excipients (inactive ingredients) are in RYKINDO?RYKINDO excipients list
DailyMed Link:RYKINDO at DailyMed
Drug patent expirations by year for RYKINDO

US Patents and Regulatory Information for RYKINDO

RYKINDO is protected by five US patents.

Patents protecting RYKINDO

Risperidone sustained release microsphere composition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SCHIZOPHRENIA IN ADULTS

Risperidone sustained release microsphere composition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SCHIZOPHRENIA IN ADULTS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Risperidone sustained release microsphere composition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SCHIZOPHRENIA IN ADULTS

Risperidone sustained release microsphere composition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF SCHIZOPHRENIA IN ADULTS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-001 Jan 13, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-004 Jan 13, 2023 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Shandong Luye RYKINDO risperidone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 212849-002 Jan 13, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for RYKINDO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Laboratorios Farmacéuticos Rovi, S.A. Okedi risperidone EMEA/H/C/005406
Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.
Authorised no no no 2022-02-14
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for RYKINDO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0196132 94C0008 Belgium ⤷  Sign Up PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.